RenovoRx Files 8-K: Material Agreement & Officer Compensation Changes
Ticker: RNXT · Form: 8-K · Filed: Jan 29, 2024 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $6,111,695, $5 M, $15 Million, $0.0001, $0.99 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, executive-compensation, corporate-governance
TL;DR
**RenovoRx just filed an 8-K about a new material agreement and officer pay changes, watch for details!**
AI Summary
RenovoRx, Inc. filed an 8-K on January 29, 2024, reporting a material definitive agreement and changes in compensatory arrangements for certain officers, with the earliest event reported on January 25, 2024. This filing indicates potential shifts in the company's financial commitments and executive incentives. For investors, this matters because changes in executive compensation and material agreements can signal new strategic directions or financial health concerns, potentially impacting future stock performance.
Why It Matters
This filing signals potential strategic shifts or financial commitments for RenovoRx, which could influence the company's operational efficiency and future profitability. Investors should monitor the details of these agreements and compensation changes as they become public.
Risk Assessment
Risk Level: medium — The filing mentions a 'material definitive agreement' and 'compensatory arrangements of certain officers' without specific details, which introduces uncertainty about their financial impact.
Analyst Insight
A smart investor would await further details on the 'material definitive agreement' and 'compensatory arrangements' to assess their financial implications before making any investment decisions.
Key Players & Entities
- RenovoRx, Inc. (company) — registrant
- January 29, 2024 (date) — date of report
- January 25, 2024 (date) — date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing by RenovoRx, Inc.?
The primary purpose of this 8-K filing is to report an 'Entry into a Material Definitive Agreement' and 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', with the earliest event reported on January 25, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 25, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What specific items are disclosed under 'ITEM INFORMATION' in this 8-K?
The specific items disclosed under 'ITEM INFORMATION' are 'Entry into a Material Definitive Agreement', 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.
What is RenovoRx, Inc.'s Central Index Key (CIK)?
RenovoRx, Inc.'s Central Index Key (CIK) is 0001574094, as listed under 'COMPANY DATA' in the filing.
What is the business address and phone number of RenovoRx, Inc. as per this filing?
According to the filing, RenovoRx, Inc.'s business address is 4546 El Camino Real, Suite B1, Los Altos, CA 94022, and their business phone number is (650) 284-4433.
Filing Stats: 1,536 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-01-29 09:06:07
Key Financial Figures
- $6,111,695 — h we raised aggregate gross proceeds of $6,111,695 (the "Offering"). Under the provisions
- $5 M — ions required to close the Offering was $5 Million, which minimum amount was satisfi
- $15 Million — ed, and the maximum offering amount was $15 Million. T he date by which the minimum offerin
- $0.0001 — Shares") of our common stock, par value $0.0001 per share (the "Common Stock") and Comm
- $0.99 — ). Investors paid a purchase price of $0.99 for each Share and related Investor War
- $1.10 — traday volume weighted average price of $1.10 for our shares of Common Stock on the N
- $1.22 — to the Company paid a purchase price of $1.22 for each Share and related Investor War
- $0.125 — icing Date, plus an attributed price of $0.125 per Warrant as required by Nasdaq. The
- $508,043 — the Company to the Placement Agent were $508,043. The Company also paid the Placement Ag
- $25,000 — e Company also paid the Placement Agent $25,000 as a non-accountable expense fee in con
- $1.08 — n issuance, and at an exercise price of $1.08 per share, under the Company's 2021 Omn
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex10-1.htm (EX-10.1) — 139KB
- ex10-2.htm (EX-10.2) — 8KB
- ex10-3.htm (EX-10.3) — 89KB
- ex10-4.htm (EX-10.4) — 86KB
- ex10-5.htm (EX-10.5) — 75KB
- ex99-1.htm (EX-99.1) — 19KB
- ex10-4_001.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-004083.txt ( ) — 736KB
- rnxt-20240129.xsd (EX-101.SCH) — 3KB
- rnxt-20240129_lab.xml (EX-101.LAB) — 33KB
- rnxt-20240129_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RenovoRx, Inc. Date: January 29, 2024 By: /s/ Shaun Bagai Name: Shaun R. Bagai Title: Chief Executive Officer 4